This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Jeffrey S. Dover, MD, FRCPC; Kenneth A. Arndt, MD

JAMA. 1995;273(21):1668-1670.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Calcipotriene ointment, a synthetic structural analogue of 1,25-dihidroxycholecalciferol, has recently been approved for the treatment of moderate plaque psoriasis by the Food and Drug Administration. Ten years ago, 1,25-dihidroxycholecalciferol was noted to inhibit the proliferation of psoriatic fibroblasts in culture.¹ This finding, along with the fact that a patient being treated with 1-hydroxyvitamin D₃ for osteoporosis noted marked improvement in her psoriasis, stimulated investigators to assess the effect of a variety of analogues of vitamin D on psoriasis. Calcipotriene (calcipotriol) is recognized with equal affinity by the 1,25-dihidroxycholecalciferol receptor but has 100 times less effect on calcium metabolism than does vitamin D.² The drug is believed to exert its therapeutic effect through inhibition of keratinocyte proliferation and increasing terminal differentiation of keratinocytes.

Placebo-controlled, randomized, double-blind trials have demonstrated the effectiveness (80% of patients treated for 6 months demonstrate at least moderate improvement), rapid activity, and safety of . . . [Full Text PDF of this Article]

Author Affiliations
New England Deaconess Hospital and Harvard Medical School, Boston, Mass; Beth Israel Hospital and Harvard Medical School, Boston, Mass

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?